Skip to main content
OpenTrials

Clinical trial condition

Flaviviridae Infections

Explore clinical trials studying Flaviviridae Infections. Study availability and eligibility vary by location and protocol.

2,144 public trials 77 recruiting studies
Refine in advanced search Browse all conditions

Flaviviridae Infections trial results

Completed

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

NCT01625338

Conditions
Blood-Borne Infections, Chronic Disease, Chronic Hepatitis C, +15 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Franco Felizarta, MD Bakersfield, California, United States
  • Arrowhead Regional Medical Center Colton, California, United States
  • Southern California Transplantation Institute, Research Foundation Liver Center Coronado, California, United States
View all 175 locations
View Trial Details
Completed

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

NCT01979939

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • Scripps Clinic La Jolla, California, United States
  • Medical Associates Research Group San Diego, California, United States
  • Quest Clinical Research San Francisco, California, United States
  • University Of Colorado Denver & Hospital Aurora, Colorado, United States
View all 66 locations
View Trial Details
Completed

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

NCT02032888

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • University Of Alabama At Birmingham Birmingham, Alabama, United States
  • Pacific Oaks Medical Group Beverly Hills, California, United States
  • Va Long Beach Healthcare System Long Beach, California, United States
  • Peter J Ruane Md Inc Los Angeles, California, United States
View all 37 locations
View Trial Details
Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

NCT00874770

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Alabama Liver & Digestive Specialists (Alds) Montgomery, Alabama, United States
  • University Of Colorado Denver & Hospital Aurora, Colorado, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Mercy Medical Center Baltimore, Maryland, United States
View all 14 locations
View Trial Details
Completed

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

NCT01359644

Conditions
Blood-Borne Infections, Chronic Disease, Chronic Hepatitis C, +15 more
Locations
  • Southern California Liver Centers Coronado, California, United States
  • Research And Education, Inc. San Diego, California, United States
  • University Of Colorado Denver & Hospital Aurora, Colorado, United States
  • University Of Florida Hepatology Gainesville, Florida, United States
View all 18 locations
View Trial Details
Completed

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

NCT01125189

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Alabama Liver & Digestive Specialists (Alds) Montgomery, Alabama, United States
  • Scripps Clinic La Jolla, California, United States
  • Cli Los Angeles, California, United States
  • Desta Digestive Disease Medical Center San Diego, California, United States
View all 64 locations
View Trial Details
Completed

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

NCT02296905

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Site Reference ID/Investigator# 130589 Miami, Florida, United States
  • Site Reference ID/Investigator# 130591 Orlando, Florida, United States
  • Site Reference ID/Investigator# 130588 San Antonio, Texas, United States
  • Site Reference ID/Investigator# 130590 Grafton, New Zealand
View Trial Details

Related conditions